SCHEMBL1785903

SCHEMBL1785903

COC(=O)c1cc(-n2cccn2)c(Cl)cc1Cl

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.41
MEN1 O00255 5/20 0.41
KMT2A Q03164 5/20 0.41
ALDH1A1 P00352 5/20 0.41
LMNA P02545 3/20 0.41
KDM4E B2RXH2 2/20 0.41
GAA P10253 1/20 0.41
G6PD P11413 1/20 0.41
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
GHSR Q92847 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
ACLY P53396 1/20 0.37
AVPR2 P30518 1/20 0.37
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1784767 0.89 HCAR1 (0.41) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL1784466 0.88 GHSR (0.42) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL1784464 0.88 ACLY (0.42) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL1786846 0.84 HCAR1 (0.47) ALDH1A1LMNAKDM4EGHSRSMN1; SMN2
SCHEMBL1784772 0.84 HSP90AA1 (0.37) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL3704400 0.82 ALDH1A1 (0.46) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL1786708 0.81 CAPN1 (0.47) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL18094315 0.80 MAPT (0.48) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL1785879 0.78 NPC1 (0.44) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL27787386 0.77 MYC (0.54) MAPTMEN1KMT2AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130203730-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2013-08-08 US disclosed
EP-2607357-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS Astrazeneca AB (SE) 2013-06-26 EP disclosed
US-20120115845-A1 THERAPEUTIC AGENTS ALLEN JACK MCQUEEN (GB) 2012-05-10 US disclosed
US-20110124621-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2011-05-26 US disclosed
EP-2205576-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS AstraZeneca AB (SE) 2010-07-14 EP disclosed
US-20090186870-A1 Therapeutic Agents - 802 ASTRAZENECA AB (SE) 2009-07-23 US disclosed
WO-2009047558-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2009-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130203730-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS GPR119, GHSR, GLP1R MAPT 3413/4885MEN1 2250/4885KMT2A 1721/4885
US-20120115845-A1 THERAPEUTIC AGENTS GPR119, MC2R, MC4R MAPT 4086/4885MEN1 692/4885KMT2A 3139/4885
US-20090186870-A1 Therapeutic Agents - 802 GPR119, SLC5A2, MC2R MAPT 4300/4885MEN1 1253/4885KMT2A 2304/4885
US-20110124621-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS GPR119, GHSR, GLP1R MAPT 3413/4885MEN1 2250/4885KMT2A 1721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.